Abstract: Isolated regulatory B cells are disclosed, and compositions including these isolated regulatory B cells. The isolated regulatory B cells are mammalian and express T cell immunoglobulin mucin-1 (TIM-1). In some embodiments the regulatory B cells produce IL-10. Methods for treating a subject with an immune-mediated disorder are disclosed. These methods include administering to the subject a therapeutically effective amount of a composition including regulatory B cells, thereby treating the immune mediated disorder in the subject. Methods are also disclosed for treating a subject with an immune-mediated disorder, wherein the methods include administering to the subject a therapeutically effective amount of an antibody that specifically binds TIM-1, wherein the antibody is activates TIM-1+CD19+ B cells. Methods are also disclosed for assessing the immune status of a subject.

Abstract: The invention features methods, compositions, and kits for treating prosthetic joint infections, foreign body infections, infectious arthritis, and osteomyelitis

Abstract: The present invention provides methods for screening antimicrobial agents that make use of mutated microbial polypeptides. Because these polypeptides have biological activity and result in increased antimicrobial drug resistance, candidate compounds that specifically target these polypeptides provide therapeutics or therapeutic lead compounds for treating infections caused by drug resistant microbial pathogens.

Abstract: The invention features two novel antibiotics, termed 15352A and 15352B, having the structures shown in the figures.